EHA 2021 | Rusfertide reduces need for therapeutic phlebotomy in PV patients
Marina Kremyanskaya, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, gives an update on the Phase II PTG-300-04 trial (NCT04057040) investigating rusfertide, a hepcidin mimetic, for the reduction of requirement for phlebotomy in patients with polycythemia vera (PV). Dr Kremyanskaya gives an overview of the rationale for the trial, highlighting challenges in the management of patients with PV, and reports preliminary results which demonstrated that the need for phlebotomy was reduced in patients receiving rusfertide. Dr Kremyanskaya comments on the key findings of the study so far, and discusses the safety profile of rusfertide in this cohort of patients. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Marina Kremyanskaya, MD, PhD, has participated in a consultancy role for Protagonist Therapeutics.
